These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 20864814)
21. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164 [TBL] [Abstract][Full Text] [Related]
22. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823 [TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833 [TBL] [Abstract][Full Text] [Related]
24. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947 [TBL] [Abstract][Full Text] [Related]
25. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Li X; Ma SJ; Liu X; Jiang LN; Zhou JH; Xiong YQ; Ding H; Chen Q Hum Vaccin Immunother; 2014; 10(12):3579-93. PubMed ID: 25668666 [TBL] [Abstract][Full Text] [Related]
28. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643 [TBL] [Abstract][Full Text] [Related]
29. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K mBio; 2020 Apr; 11(2):. PubMed ID: 32265332 [TBL] [Abstract][Full Text] [Related]
30. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987 [TBL] [Abstract][Full Text] [Related]
31. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Huang LM; Lin TY; Chiu CH; Chiu NC; Chen PY; Yeh SJ; Boaz M; Hutagalung Y; Bouckenooghe A; Feroldi E Vaccine; 2014 Sep; 32(41):5363-9. PubMed ID: 24631095 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial. Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119 [TBL] [Abstract][Full Text] [Related]
33. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China. Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687 [TBL] [Abstract][Full Text] [Related]
35. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647 [TBL] [Abstract][Full Text] [Related]
36. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization. Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine. Furuya-Kanamori L; Gyawali N; Mills DJ; Mills C; Hugo LE; Devine GJ; Lau CL J Travel Med; 2023 Apr; 30(2):. PubMed ID: 36308439 [TBL] [Abstract][Full Text] [Related]
38. Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study. Jelinek T; Burchard GD; Dieckmann S; Bühler S; Paulke-Korinek M; Nothdurft HD; Reisinger E; Ahmed K; Bosse D; Meyer S; Costantini M; Pellegrini M J Travel Med; 2015; 22(4):225-31. PubMed ID: 25997707 [TBL] [Abstract][Full Text] [Related]